voxilaprevir

Drug Overview

Voxilaprevir is a third-generation, direct-acting antiviral (DAA) agent utilized as a component of salvage therapy for chronic Hepatitis C virus (HCV) infection. As a SMALL MOLECULE inhibitor, it is exclusively available in a fixed-dose combination with sofosbuvir (an NS5B polymerase inhibitor) and velpatasvir (an NS5A inhibitor). This pan-genotypic regimen is specifically designed to address viral resistance in patients who have previously failed other DAA therapies.

• Generic Name: voxilaprevir (co-formulated with sofosbuvir and velpatasvir)
• US Brand Names: Vosevi
• Route of Administration: Oral tablets
• FDA Approval Status: Fully FDA-approved.
• Drug Class: Direct-Acting Antiviral (HCV NS3/4A Protease Inhibitor)

What Is It and How Does It Work? (Mechanism of Action)

Voxilaprevir is an advanced SMALL MOLECULE acting as a highly specialized TARGETED THERAPY against the Hepatitis C virus (HCV).

1. Protease Inhibition

At the molecular level, voxilaprevir functions specifically as an HCV pangenotypic NS3/4A protease inhibitor. When HCV enters a hepatocyte, it produces a non-functional polyprotein chain. To become infectious, this chain must be cut into smaller pieces by the viral NS3/4A protease enzyme.

2. Replication Blockade

Voxilaprevir directly binds to and blocks the active site of this specific protease. By jamming the enzyme, the drug prevents the virus from processing its proteins. Without these proteins, HCV cannot assemble new particles or replicate. This physiological blockade halts the infection, allowing the immune system to clear the virus and restore hepatic function.

FDA-Approved Clinical Indications

Primary Hepatology Indications:

• Treatment of Chronic Hepatitis C: Voxilaprevir is strictly indicated for adult patients with chronic HCV across all genotypes (1-6). It is a “salvage therapy” prescribed specifically for patients who previously failed older antiviral regimens (specifically those containing an NS5A inhibitor). Eradicating this virus permanently halts liver inflammation and prevents the progression of liver fibrosis to severe cirrhosis.

Other Approved & Off-Label Uses:

• Because voxilaprevir exclusively targets a viral enzyme unique to Hepatitis C, there are no approved or off-label uses for broader gastrointestinal conditions such as Crohn’s disease, Ulcerative Colitis, GERD, IBS, or recurrent C. diff infections.

Dosage and Administration Protocols

Adherence to the daily dosing schedule is incredibly critical to successfully curing the Hepatitis C infection and preventing drug-resistant viral mutations.

• 
  Timing: Take simultaneously with food to ensure proper gastrointestinal absorption of the voxilaprevir component.
• Hepatic Insufficiency: Strictly contraindicated for patients with moderate-to-severe hepatic impairment (Child-Pugh Class B or C).
• Renal Insufficiency: No dosage adjustment is required for patients with renal impairment, including those on routine dialysis.

Clinical Efficacy and Research Results

The clinical efficacy of this specialized antiviral regimen is supported by rigorous data from the POLARIS phase 3 clinical trials.

Researchers measured the primary efficacy endpoint known as Sustained Virologic Response at 12 weeks (SVR12). Achieving a confirmed SVR12 means the Hepatitis C virus remains entirely undetectable in the bloodstream 12 weeks post-treatment, firmly recognized as a definitive virologic cure. Across all viral genotypes, approximately 96% to 97% of patients treated with the complete 12-week voxilaprevir-based regimen achieved an SVR12.

Safety Profile and Side Effects

BLACK BOX WARNING: This medication carries a severe FDA Black Box Warning regarding a very dangerous risk of Hepatitis B virus (HBV) reactivation. In patients co-infected with HCV and HBV, curing HCV can unexpectedly cause dormant HBV to aggressively reactivate, potentially leading to fulminant hepatitis and hepatic failure.

Common Side Effects (>10% frequency):

• Headache
• Fatigue and lethargy
• Diarrhea and GI upset
• Mild nausea

Serious Adverse Events:

• Hepatic Decompensation: Risk of sudden liver failure in patients with advanced cirrhosis.
• Severe Bradycardia: Taking this TARGETED THERAPY alongside amiodarone can cause a dangerously slow heart rate requiring immediate cardiac intervention.

Connection to Mucosal Immunology and Microbiome Research

While this TARGETED THERAPY specifically treats the liver directly, completely curing Hepatitis C has a profound impact on the larger gut-liver axis and mucosal immunology.

Chronic HCV infection causes severe systemic inflammation and dangerous portal hypertension, which physically damages the intestinal epithelial barrier and heavily increases gut permeability. This compromised state allows harmful bacterial toxins to leak from the gut microbiome directly into the bloodstream, damaging the liver further through a toxic inflammatory feedback loop.

Achieving a complete virologic cure rapidly reduces portal vein pressures and substantially lowers circulating inflammatory cytokines systemically. This calming effect allows the intestinal barrier to initiate robust mucosal healing and beautifully restores a healthier physiological balance to the localized gut microbiome.

Disclaimer: This research represents emerging frontiers in gastroenterology and is currently in the preclinical or early investigational phase. This information is intended for educational exploration and does not constitute definitive clinical evidence or established standards of care.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Diagnostics: Quantitative HCV RNA blood test to confirm viral load and identify genotype.
• Organ Function: Liver Function Tests (LFTs) and bilirubin panels to calculate the Child-Pugh score.
• Specialized Testing: Strict mandatory screening for Hepatitis B surface antigen (HBsAg) and core antibody (anti-HBc) is required.
• Screening: Review of all medications for interactions with statins, anticonvulsants, and acid-reducing medications.

Monitoring and Precautions

• Vigilance: Patients must undergo a final HCV RNA test precisely 12 weeks post-treatment to officially confirm the virologic cure (SVR12).
• Lifestyle: Absolute cessation of all alcohol consumption is vital.

Do’s and Don’ts:

• DO take the pill at the exact same time every single day with a substantial meal.
• DON’T take proton pump inhibitors (PPIs) without strict doctor supervision as they may reduce drug efficacy.
• DON’T consume unregulated herbal supplements like St. John’s Wort.

Legal Disclaimer

The medical information provided in this guide is intended strictly for educational and informational purposes only. It does not replace professional medical advice, formal clinical diagnosis, or direct therapeutic treatment. Always consult a board-certified Gastroenterologist or Hepatologist. Information is based on data available as of 2026.